Pioglitazone attenuates myocardial ischemia-reperfusion injury via up-regulation of ERK and COX-2

BioScience Trends

Volumn 6, Issue 6, 2012, Pages 325-332

  Wang, Hao ^a   Zhu, Qiwei ^a   Ye, Ping ^a   Li, Zongbin ^a   Li, Yang ^a   Cao, Zeling ^a   Shen, Lin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Apoptosis; COX 2; ERK1 2; Ischemia reperfusion injury; Peroxisome proliferator activated receptor ; Pioglitazone

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-(2-AMINO-3-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; CYCLOOXYGENASE 2; FLAVONOID; MITOGEN ACTIVATED PROTEIN KINASE; PIOGLITAZONE;

ANIMAL; APOPTOSIS; ARTICLE; DRUG EFFECT; ENZYMOLOGY; GENETICS; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANILIDES; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CYCLOOXYGENASE 2; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; MALE; MYOCARDIAL REPERFUSION INJURY; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; THIAZOLIDINEDIONES;

EID: 84873432051     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2012.v6.6.325     Document Type: Article

References (26)

1. Cao Z, Ye P, Long C, Chen K, Li X, Wang H. Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats. Pharmacology. 2007; 79:184-192.
2. Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR-γ ligands in ischemia- reperfusion injury, inflammation and shock. Cardiovasc Res. 2005; 65:772-781.
3. Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM. Serine/threonine protein kinases and apoptosis. Exp Cell Res. 2000; 256:34-41.
4. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: Conservation of a three-kinase module from yeast to human. Physiol Rev. 1999; 79:143- 180.
5. Yue TL, Wang C, Gu JL, Ma XL, Kumar S, Lee JC, Feuerstein GZ, Thomas H, Maleeff B, Ohlstein EH. Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res. 2000; 86:692-
6. Shimizu N, Yoshiyama M, Omura T, Hanatani A, Kim S, Takeuchi K, Iwao H, Yoshikawa J. Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res. 1998; 38:116-124.
7. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol. 2005; 288: H971-H976.
8. Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem. 1999; 274:5038-5046.
9. Shinmura K, Nagai M, Tamaki K, Tani M, Bolli R. COX-2-derived prostacyclin mediates opioid-induced late phase of preconditioning in isolated rat hearts. Am J Physiol Heart Circ Physiol. 2002; 283:H2534- H2543.
10. Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Takano H, Bhatnagar A, Bolli R. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A. 2000; 97:10197-10202.
11. Hinmura K, Xuan YT, Tang XL, Kodani E, Han H, Zhu Y, Bolli R. Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res. 2002; 90:602-608.
12. Ye Y, Keyes KT, Zhang CF, Perez-Polo JR, Lin Y, Birnbaum Y. Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size. Cardiovasc Drugs Ther. 2010; 24:107-120.
13. Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN, Ohlstein EH, Yue TL, Ma XL. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res. 2004; 62:135-144.
14. Ye Y, Lin Y, Atar S, Huang MH, Perez-Polo JR, Uretsky BF, Birnbaum Y. Myocardial protection by pioglitazone, atorvastatin, and their combination: Mechanisms and possible interactions. Am J Physiol Heart Circ Physiol. 2006; 291:H1158-1169.
15. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol. 2010; 298:H1454-1465.
16. Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation. 1998; 97:276-281.
17. Mocanu MM, Baxter GF, Yellon DM. Caspase inhibition and limitation of myocardial infarct size: Protection against lethal reperfusion injury. Br J Pharmacol. 2000; 130:197-200.
18. Zhao ZQ, Morris CD, Budde JM, Wang NP, Muraki S, Sun HY, Guyton RA. Inhibition of myocardial apoptosis reduces infarct size and improves regional contractile dysfunction during reperfusion. Cardiovasc Res. 2003; 59:132-142.
19. Lee TM, Chou TF. Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins. Am J Physiol Heart Circ Physiol. 2003; 285:H1650-H1659.
20. Kaundal RK, Iyer S, Kumar A, Sharma SS. Protective effects of pioglitazone against global cerebral ischemic-reperfusion injury in gerbils. J Pharmacol Sci. 2009; 109:361-367.
21. Wynne AM, Mocanu MM, Yellon DM. Pioglitazone mimics preconditioning in the isolated perfused rat heart: A role for the prosurvival kinases PI3K and P42/44MAPK. J Cardiovasc Pharmacol. 2005; 46:817-822.
22. Ye Y, Hu Z, Lin Y, Zhang C, Perez-Polo JR. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-γ agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res. 2010; 87:535-544.
23. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: Targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res. 2004; 61:448-460.
24. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 2005; 11:1096-1103.
25. Neilan TG, Doherty GA, Chen G, Deflandre C, McAllister H, Butler RK, McClelland SE, Kay E, Ballou LR, Fitzgerald DJ. Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin. Am J Physiol Heart Circ Physiol. 2006; 291:H532-H536.
26. Ye Y, Lin Y, Manickavasagam S, Perez-Polo JR, Tieu BC, Birnbaum Y. Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice. Am J Physiol Heart Circ Physiol. 2008; 295:H2436-H2446.